147
129.
De Jonge E., Levi M., Stoutenbeek C.P., van deventer S.J. Current drug
treatment strategies for disseminated intravascular coagulation // Drag., 1998, v. 55,
p. 767-777.
130.
De Jonge E., Dekkers P.E., Creasey A.A. et al. Tissue factor pathway
inhibitors dose- dependently inhibit coagulation activation without influencing the
fibrinolytic and cytokine response during human endotoxemia // Blood., 2000, v.
95, p. 1124-1129.
131.
Dempfle C.E. Coagulation of sepsis // Thromb. Haemost., 2004, v. 91, p.
213-224.
132.
Dervenis C.G., Johnson C.D., Bassi C. Diagnosis, objective assessment
of severity and management of acute pancreatitis. Santorini Consensus Conference //
Inter. J. Pancreatology, 1999, v. 25, №3, p. 195-210.
133.
Dhainaut J.F., Yan S.B., Joyce D.E. et al. Treatment of drotrecogin alfa
(activated) in patients with severe sepsis with or without overt disseminated
intravascular coagulation // J. Throm. Haemost., 2004, v. 2, p. 1924-1933.
134.
Dhainaut J.F., Shorr A.F., Macians W.L. et al. Dynamic evolution of
coagulopathy in the first day of severe sepsis: relationship with mortality and organ
failure // Crit. Care Med., 2005, v. 33, p. 341-348.
135.
Eisele B., Lamy M. Clinical experience with antithrombin III
concentrates in critically ill patients with sepsis and multiple organ failure // II Semin.
Throromb. Hemostas., 1998, v.24, p. 71-80.
136.
Eisenberg P.R., Sherman L. A., Perez J., Jaffe A.S. Relationship between
plasma levels of crosslinked fibrin degradation products (XL- FDP) and the clinical
presentation of patients with myocardial infarction // Thrombos. Res., 1987, v.46, p.
109-120.
137.
Ellman G.L. Tissue sulfhydryl groups // Arch. Biochem. Biophys., 1959,
v.82, p. 70-77.
138.
Fourrier F., Jourdain M., Tournoys A. Clinical trial results with
antitrombin III in severe sepsis // Crit. Care Med., 2000, v. 28, p. S38-S43.
148
139.
Fourrier F. Recombinant human activated protein C in the treatment of
severe sepsis: an evidence-based review // Crit. Care Med., 2004, v.32, p. S534-S541.
140.
Fowkes F. G. R., Lowe G. D. O., Housley E. Cross-linked fibrin
degradation products, progression of peripheral arterial disease and risk of coronary
artery disease.// Lancet, 1993, v. 342, p. 84-86.
141.
Franchini M., Manzato F. Update on the treatment of the disseminated
intravascular coagulation // Hematology, 2004, v. 9, p. 81-85.
142.
Franchini M. Pathophisiology, diagnosis and treatment of disseminated
intravascular coagulation: an update // Clin. Lab., 2005, v.51, p. 633-639.
143.
Franchini ML, Lippi G., Manzato F. Recent acquisitions in the
pathophysiology, diagnosis and treatment of disseminated intravascular coagulation //
Trombosis J., 2006, v. 4, p.4
144.
Fry D.E. Sepsis syndrome // Am. Surg., 2000, v.66, p. 126-132.
145.
Fuchs-Buder T., De Moerloose P., Ricou B. et al. Time course of
procoagulant activity and D-dimer in bronchalveolar fluid of patients at risk for or
with acute respiratory distress syndrome // Am. J. Respir. Crit. Care Med., 1996, v.
153, p. 163-167.
146.
Galanos C., Freudenberg M.A. Mechanisms of endotoxin shock and
endotoxin hypersensivity // Immunobiol., 1993, v.187, p. 346-356.
147.
Gando S., Tedo I. Diagnostic and prognostic value of fibrinopeptides in
patients with clinically suspected pulmonary embolism // Thromb. Res., 1994, v.75,
p. 195-202.
148.
Gando S., Nanzaki S., Sasaki S. et al. Activation of the coagulation
pathway in patients with severe sepsis and septic shok // Crit. Care Med., 1998, v.26,
p. 2005-2009.
149.
Gando S., Nanzaki S., Sasaki S., Kemmotsu O. Significant correlations
between tissue factor and thrombin markers in trauma and septic patients with
disseminated intravascular coagulation // Thrombos. Haemostas., 1998, v.79, p.
1111-1115.
149
150.
Garvey M.B., Black J.M. The detection of fibrinogen/fibrin degradation
products by means of a new antibodycoated latex particle // J. Clin. Path., 1972, v.25,
p. 680-682.
151.
Geerts W., Cook D., Selby R., Etchells E. Venous thromboembolism and
its prevention in critical care // J. Crit. Care., 2002, v.17, p. 95-104.
152.
Omarov T.İ., Sultanov G.A., Ragimov V.S. The Comparative
Characteristics of the Hemostatic System İndices in the Assessment of late
Complications of Acute destructive Pancreatitis//World Journal of Medical Science
SCOPUS 8(2): 96-102, 2013
153.
Ginsberg J. S., Kearon C., Douketis J. et al. The use of D-dimer testing
and impedance plethysmographic examination in patients with clinical indications of
deep vein thrombosis// Arch. Intern. Med., 1997, v.157, p. 1077-1081.
154.
Glassman A. B.Hemostatic abnormalities assocated with cancer and its
therapy //Ann. Clin. Lab. Sci., 1997, v.27, p. 391-395.
155.
Goldhaber S.Z. Pulmonary embolism // Lancet, 2004, v.363, p. 1295-
1305.
156.
Gouin-Thibault I., Samana M. M.Labaratory diagnosis of the
thrombophilie state in cancer patients. // Semin. Thrombos. Haemostas., 1999, v. 25.
p.167-172.
157.
Gutteridge J.M., Mitchell J. Redox imbalance in the critically ill // Br.
Med. Bull., 1999, v. 55, p. 49-75.
158.
He X.L., Liu Z., Xia S.Y. Vascular endothelial injuries and changes of
blood coagulation and fibrinolysis indexes in patients with acute respiratory distress
syndrome // Clin. Med. Sci. J., 2004, v.19, p. 252-256.
159.
Heence D.L., Kirschstein W., Dempfle C.E. Shock-induced alterations in
hemostasis // Klin. Wochenschr., 1986, v.64, p. 14-17.
160.
Hesse R., Tritschler W., Castelfranchi G., Bablor W. Antithrombin III:
referenzwerte mit einem chromogene substrat (Chromozym TH) // Blut., 1981, Bd.
42, p. 227-234.
Dostları ilə paylaş: |